Dyne, Avidity initiated at outperform by RBC on DM1 drugs
seekingalpha
2024-11-27
Hailshadow/iStock via Getty Images
RBC Capital has initiated coverage of Dyne Therapeutics (NASDAQ:DYN) and Avidity Biosciences (NASDAQ:RNA) with outperform ratings, commenting that the two companies may have “cracked the code” for muscle with their respective drug platforms.
RBC noted that while Avidity (RNA) is
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。
熱議股票
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10